Clindamycin and primaquine therapy for mild-to-moderate episodes of pneumocystis carinii pneumonia in patients with aids: Aids clinical trials group 044

John R. Black; Judith Feinberg; Robert L. Murphy; Robert J. Fass; Dianne Finkelstein; Bisher Akil; Sharon Safrin; John T. Carey; John Stansell; Joseph F. Plouffe; Weili He; Brent Shelton; Fred R. Sattler

doi:10.1093/clinids/18.6.905

Clindamycin and primaquine therapy for mild-to-moderate episodes of pneumocystis carinii pneumonia in patients with aids: Aids clinical trials group 044

John R. Black
, Judith Feinberg
, Robert L. Murphy
, Robert J. Fass
, Dianne Finkelstein
, Bisher Akil
, Sharon Safrin
, John T. Carey
, John Stansell
, Joseph F. Plouffe
, Weili He
, Brent Shelton
, Fred R. Sattler

Internal Medicine

Producción científica: Article › revisión exhaustiva

52 Citas (Scopus)

Resumen

The objective of this prospective, noncomparative study was to assess the safety and efficacy of clindamycin and primaquine therapy for mild-to-moderate pneumocystis pneumonia (defined as a difference of <40 mm Hg between the alveolar and the arterial oxygen determinations) in patients with AIDS. In the first part of the study, 22 patients were treated with iv clindamycin (900 mg every 8 hours) for the first 10 days, and then their therapy was switched to oral clindamycin (450 mg every 6 hours) for an additional 11 days. In the second part of the study, 38 patients were treated entirely with oral clindamycin (600 mg every 8 hours). All patients were treated with oral primaquine base (30 mg once daily). Fifty-five (92%) of 60 patients responded to the study treatment. Forty-six (77%) of 60 patients completed a full course of therapy. Of the nine patients with treatment-limiting toxic effects, four had only a mild rash. This study indicates that the combination of clindamycin and primaquine is an effective and well-tolerated therapy for mild-to-moderate pneumocystis pneumonia in patients with AIDS. Entirely oral therapy appears to be as effective as initial therapy with iv clindamycin.

Idioma original	English
Páginas (desde-hasta)	905-913
Número de páginas	9
Publicación	Clinical Infectious Diseases
Volumen	18
N.º	6
DOI	https://doi.org/10.1093/clinids/18.6.905
Estado	Published - jun 1994

Nota bibliográfica

Funding Information:
Received 4 August 1993; revised 24 January 1994. This work was presented in part at the 5th International Conference on AIDS held on 6 June 1989 in Montreal (abstract no T.B.P.30) and at the 7th International Conference on AIDS held on 20 June 1991 in Florence. Italy (abstract no Th.B.42). Informed consent was obtained from all patients. and the guidelines for human experimentation of the U.S. Department of Health and Human Services were followed. Approval was obtained from the Committees on the Protection of Human Subjects at each participating institution. Grant support: The AIDS Clinical Trials Units at the participating institutions receive grant support from the Division ofAIDS of the National Institute of Allergy and Infectious Diseases. * Present address: Methodist Hospital of Indiana. Indianapolis. Indiana. t Present address: Johns Hopkins University Hospital. Baltimore. Maryland. t Present address: Department of Biostatistics. University of North Carolina. Chapel Hill. North Carolina. Reprints or correspondence: Dr. John R. Black. Methodist Hospital of Indiana. 1633 North Capitol Street. Suite 700. Indianapolis. Indiana 46202.

Financiación

Received 4 August 1993; revised 24 January 1994. This work was presented in part at the 5th International Conference on AIDS held on 6 June 1989 in Montreal (abstract no T.B.P.30) and at the 7th International Conference on AIDS held on 20 June 1991 in Florence. Italy (abstract no Th.B.42). Informed consent was obtained from all patients. and the guidelines for human experimentation of the U.S. Department of Health and Human Services were followed. Approval was obtained from the Committees on the Protection of Human Subjects at each participating institution. Grant support: The AIDS Clinical Trials Units at the participating institutions receive grant support from the Division ofAIDS of the National Institute of Allergy and Infectious Diseases. * Present address: Methodist Hospital of Indiana. Indianapolis. Indiana. t Present address: Johns Hopkins University Hospital. Baltimore. Maryland. t Present address: Department of Biostatistics. University of North Carolina. Chapel Hill. North Carolina. Reprints or correspondence: Dr. John R. Black. Methodist Hospital of Indiana. 1633 North Capitol Street. Suite 700. Indianapolis. Indiana 46202.

Financiadores
National Institute of Allergy and Infectious Diseases
AIDS Clinical Trials Group

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Acceder al documento

10.1093/clinids/18.6.905

Otros archivos y enlaces

Citar esto

Black, J. R., Feinberg, J., Murphy, R. L., Fass, R. J., Finkelstein, D., Akil, B., Safrin, S., Carey, J. T., Stansell, J., Plouffe, J. F., He, W., Shelton, B., & Sattler, F. R. (1994). Clindamycin and primaquine therapy for mild-to-moderate episodes of pneumocystis carinii pneumonia in patients with aids: Aids clinical trials group 044. Clinical Infectious Diseases, 18(6), 905-913. https://doi.org/10.1093/clinids/18.6.905

@article{ce38673d57fc45108ad7c825d945b87c,

title = "Clindamycin and primaquine therapy for mild-to-moderate episodes of pneumocystis carinii pneumonia in patients with aids: Aids clinical trials group 044",

abstract = "The objective of this prospective, noncomparative study was to assess the safety and efficacy of clindamycin and primaquine therapy for mild-to-moderate pneumocystis pneumonia (defined as a difference of <40 mm Hg between the alveolar and the arterial oxygen determinations) in patients with AIDS. In the first part of the study, 22 patients were treated with iv clindamycin (900 mg every 8 hours) for the first 10 days, and then their therapy was switched to oral clindamycin (450 mg every 6 hours) for an additional 11 days. In the second part of the study, 38 patients were treated entirely with oral clindamycin (600 mg every 8 hours). All patients were treated with oral primaquine base (30 mg once daily). Fifty-five (92\%) of 60 patients responded to the study treatment. Forty-six (77\%) of 60 patients completed a full course of therapy. Of the nine patients with treatment-limiting toxic effects, four had only a mild rash. This study indicates that the combination of clindamycin and primaquine is an effective and well-tolerated therapy for mild-to-moderate pneumocystis pneumonia in patients with AIDS. Entirely oral therapy appears to be as effective as initial therapy with iv clindamycin.",

author = "Black, \{John R.\} and Judith Feinberg and Murphy, \{Robert L.\} and Fass, \{Robert J.\} and Dianne Finkelstein and Bisher Akil and Sharon Safrin and Carey, \{John T.\} and John Stansell and Plouffe, \{Joseph F.\} and Weili He and Brent Shelton and Sattler, \{Fred R.\}",

note = "Funding Information: Received 4 August 1993; revised 24 January 1994. This work was presented in part at the 5th International Conference on AIDS held on 6 June 1989 in Montreal (abstract no T.B.P.30) and at the 7th International Conference on AIDS held on 20 June 1991 in Florence. Italy (abstract no Th.B.42). Informed consent was obtained from all patients. and the guidelines for human experimentation of the U.S. Department of Health and Human Services were followed. Approval was obtained from the Committees on the Protection of Human Subjects at each participating institution. Grant support: The AIDS Clinical Trials Units at the participating institutions receive grant support from the Division ofAIDS of the National Institute of Allergy and Infectious Diseases. * Present address: Methodist Hospital of Indiana. Indianapolis. Indiana. t Present address: Johns Hopkins University Hospital. Baltimore. Maryland. t Present address: Department of Biostatistics. University of North Carolina. Chapel Hill. North Carolina. Reprints or correspondence: Dr. John R. Black. Methodist Hospital of Indiana. 1633 North Capitol Street. Suite 700. Indianapolis. Indiana 46202.",

year = "1994",

month = jun,

doi = "10.1093/clinids/18.6.905",

language = "English",

volume = "18",

pages = "905--913",

number = "6",

}

Black, JR, Feinberg, J, Murphy, RL, Fass, RJ, Finkelstein, D, Akil, B, Safrin, S, Carey, JT, Stansell, J, Plouffe, JF, He, W, Shelton, B & Sattler, FR 1994, 'Clindamycin and primaquine therapy for mild-to-moderate episodes of pneumocystis carinii pneumonia in patients with aids: Aids clinical trials group 044', Clinical Infectious Diseases, vol. 18, n.º 6, pp. 905-913. https://doi.org/10.1093/clinids/18.6.905

TY - JOUR

T1 - Clindamycin and primaquine therapy for mild-to-moderate episodes of pneumocystis carinii pneumonia in patients with aids

T2 - Aids clinical trials group 044

AU - Black, John R.

AU - Feinberg, Judith

AU - Murphy, Robert L.

AU - Fass, Robert J.

AU - Finkelstein, Dianne

AU - Akil, Bisher

AU - Safrin, Sharon

AU - Carey, John T.

AU - Stansell, John

AU - Plouffe, Joseph F.

AU - He, Weili

AU - Shelton, Brent

AU - Sattler, Fred R.

N1 - Funding Information: Received 4 August 1993; revised 24 January 1994. This work was presented in part at the 5th International Conference on AIDS held on 6 June 1989 in Montreal (abstract no T.B.P.30) and at the 7th International Conference on AIDS held on 20 June 1991 in Florence. Italy (abstract no Th.B.42). Informed consent was obtained from all patients. and the guidelines for human experimentation of the U.S. Department of Health and Human Services were followed. Approval was obtained from the Committees on the Protection of Human Subjects at each participating institution. Grant support: The AIDS Clinical Trials Units at the participating institutions receive grant support from the Division ofAIDS of the National Institute of Allergy and Infectious Diseases. * Present address: Methodist Hospital of Indiana. Indianapolis. Indiana. t Present address: Johns Hopkins University Hospital. Baltimore. Maryland. t Present address: Department of Biostatistics. University of North Carolina. Chapel Hill. North Carolina. Reprints or correspondence: Dr. John R. Black. Methodist Hospital of Indiana. 1633 North Capitol Street. Suite 700. Indianapolis. Indiana 46202.

PY - 1994/6

Y1 - 1994/6

N2 - The objective of this prospective, noncomparative study was to assess the safety and efficacy of clindamycin and primaquine therapy for mild-to-moderate pneumocystis pneumonia (defined as a difference of <40 mm Hg between the alveolar and the arterial oxygen determinations) in patients with AIDS. In the first part of the study, 22 patients were treated with iv clindamycin (900 mg every 8 hours) for the first 10 days, and then their therapy was switched to oral clindamycin (450 mg every 6 hours) for an additional 11 days. In the second part of the study, 38 patients were treated entirely with oral clindamycin (600 mg every 8 hours). All patients were treated with oral primaquine base (30 mg once daily). Fifty-five (92%) of 60 patients responded to the study treatment. Forty-six (77%) of 60 patients completed a full course of therapy. Of the nine patients with treatment-limiting toxic effects, four had only a mild rash. This study indicates that the combination of clindamycin and primaquine is an effective and well-tolerated therapy for mild-to-moderate pneumocystis pneumonia in patients with AIDS. Entirely oral therapy appears to be as effective as initial therapy with iv clindamycin.

AB - The objective of this prospective, noncomparative study was to assess the safety and efficacy of clindamycin and primaquine therapy for mild-to-moderate pneumocystis pneumonia (defined as a difference of <40 mm Hg between the alveolar and the arterial oxygen determinations) in patients with AIDS. In the first part of the study, 22 patients were treated with iv clindamycin (900 mg every 8 hours) for the first 10 days, and then their therapy was switched to oral clindamycin (450 mg every 6 hours) for an additional 11 days. In the second part of the study, 38 patients were treated entirely with oral clindamycin (600 mg every 8 hours). All patients were treated with oral primaquine base (30 mg once daily). Fifty-five (92%) of 60 patients responded to the study treatment. Forty-six (77%) of 60 patients completed a full course of therapy. Of the nine patients with treatment-limiting toxic effects, four had only a mild rash. This study indicates that the combination of clindamycin and primaquine is an effective and well-tolerated therapy for mild-to-moderate pneumocystis pneumonia in patients with AIDS. Entirely oral therapy appears to be as effective as initial therapy with iv clindamycin.

UR - https://www.scopus.com/pages/publications/0028335216

UR - https://www.scopus.com/pages/publications/0028335216#tab=citedBy

U2 - 10.1093/clinids/18.6.905

DO - 10.1093/clinids/18.6.905

M3 - Article

C2 - 8086551

AN - SCOPUS:0028335216

SN - 1058-4838

VL - 18

SP - 905

EP - 913

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 6

ER -

Clindamycin and primaquine therapy for mild-to-moderate episodes of pneumocystis carinii pneumonia in patients with aids: Aids clinical trials group 044

Resumen

Nota bibliográfica

Financiación

ODS de las Naciones Unidas

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto